UW-Madison Startup Cellular Dynamics Licenses Cardiovascular Stem Cell IP from NY's Mount Sinai

According to CDI, the exclusive licensing agreement broadens what it believes to be its leading IP position in the area of using stem cells as starting materials to produce large quantities of cells, particularly cardiomyocytes, as tools for drug screening.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.